Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

  • STATUS
    Recruiting
  • participants needed
    174
  • sponsor
    Associazione Qol-one
Updated on 23 January 2021
platelet count
hysterectomy
stem cell transplantation
myeloid leukemia
anemia
myelodysplastic syndromes
filgrastim
granulocyte colony stimulating factor
cell transplantation
leukemia
bone marrow procedure
cytopenia
azacitidine
lenalidomide
colony stimulating factor
blood transfusion
g-csf
platelet transfusion
eltrombopag
neutropenia
autoimmune thrombocytopenia

Summary

Myelodysplastic syndromes (MDS) prevail in older age and are characterized by ineffective erythropoiesis and peripheral cytopenias. Supportive therapy is the main therapeutic option for most patients. Quality of Life (QoL) is mainly deteriorated by anemia and by the limitations associated with thrombocytopenia, neutropenia and transfusion dependence. The only available treatment for severe thrombocytopenia, in the presence of bleeding, is platelet transfusion.

Eltrombopag is an orally bioavailable agonist of the thrombopoietin receptor. In adult patients with chronic immune thrombocytopenia (ITP), Eltrombopag rapidly increases platelet counts and significantly reduces bleeding episodes during treatment. Eltrombopag is well tolerated. In 2007, Eltrombopag has received the Orphan Drug Designation for the treatment of ITP (EMEA/OD/031/07), and in 2008 the Food and Drug Association approved Eltrombopag for the treatment of ITP refractory or resistant. It has been shown that in patients affected by MDS and by acute myeloid leukemia, Eltrombopag neither increases the proliferation, nor the clonogenic growth capacity of bone marrow blasts. Furthermore, Eltrombopag induces an increase in the megakaryocytic differentiation and in the formation of normal megakaryocytic colonies. These results provide the rationale for pursuing further research on Eltrombopag for the treatment of thrombocytopenia in case of MDS.

The study is open to adult patients with myelodysplastic syndrome (MDS) with thrombocytopenia and low- or intermediate-1 IPSS risk (Index Prognostic Score System).

Severe thrombocytopenia associated with MDS may lead to death from hemorrhage, even in low prognostic risk patients. The benefit of platelet transfusion is short-termed. Patients become refractory in the long term. The availability of a treatment that induces the increase of platelet count is extremely important, either in terms of quality of life, and in overall survival.

Details
Condition Bone marrow disorder, Preleukemia, MYELODYSPLASTIC SYNDROME, Thrombocytopenia, Myelodysplastic Syndromes (MDS), Thrombocytopenia and Thrombocytopenia Prevention, myelodysplastic syndromes, myelodysplastic syndrome (mds)
Treatment Placebo, Eltrombopag/Revolade
Clinical Study IdentifierNCT02912208
SponsorAssociazione Qol-one
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Adult subjects (18 years of age or older) with low or intermediate-1 IPSS risk MDS and stable disease
Subjects must have a platelet count taken within the 4 weeks prior to randomization that is <30 Gi/L
Subjects must be ineligible or relapsed or refractory to receive other treatment options (such as azacitidine or lenalidomide) and must be ineligible to receive intensive chemotherapy or autologous/allogeneic stem cell transplantation
Subjects must have platelet count and platelet transfusion data available over a period of 8 weeks prior to randomization
During the 2 months prior to randomization, subjects must have a baseline Bone Marrow examination which includes cytomorphology and cytogenetics. Histopathology should be performed
Erythropoiesis-stimulating agents (ESAs) in anemic subjects or granulocyte colonystimulating factor (G-CSF) in subjects with severe neutropenia and recurrent infections are allowed during the study as per accepted standards. Subjects who enter the study on ESAs or G-CSF should continue at the same dose schedule until the optimal dose of study medication has been established
ECOG (Eastern Cooperative Oncology Group) Performance Status 0-3
Subject is able to understand and comply with protocol requirements and instructions
Subject has signed and dated informed consent
Adequate baseline organ function defined by the criteria below
total bilirubin (except for Gilbert's Syndrome) 1.5 x Upper Limit Normal
Alanine aminotransferase and Aspartate aminotransferase 3 x Upper Limit Normal
creatinine 2 x Upper Limit Normal albumin must not be below the lower limit of
normal by more than 20%
\. Subject is practicing an acceptable method of contraception. Female
subjects (or female partners of male subjects) must either be of non-
childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal
ligation or post-menopausal >1 year), or of childbearing potential and use of
an highly effective method of contraception from 2 weeks prior to
administration of study medication, throughout the study, and 28 days after
completion or premature discontinuation from the study

Exclusion Criteria

MDS with intermediate-2 or high IPSS risk
History of treatment for cancer other than MDS with systemic chemotherapy and/or radiotherapy within the last 2 years
History of treatment with romiplostim or other Thrombopoietin receptor agonists
Pre-existing cardiovascular disease (including congestive heart failure, New York Heart Association Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. persistent atrial fibrillation), or subjects with a QTc >450 msec (QTc >480 msec for subjects with Bundle Branch Block)
BM fibrosis that leads to an inability to aspirate marrow for assessment
Peripheral monocytosis > 1000/uL prior to Day 1 of study medication
Leukocytosis >=25,000/uL prior to Day 1 of study medication
Female subjects who are nursing or pregnant (positive serum or urine Beta-human chorionic gonadotropin [B-hCG] pregnancy test) at screening or pre-dose on Day 1
Current alcohol or drug abuse
Treatment with an Investigational Product within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication
Active and uncontrolled infections
Subjects infected with Hepatitis B, C or Human Immunodeficiency Virus (HIV)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note